We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Bladder Cancer

Journal Scan / Research · April 14, 2021

Cost-Effectiveness Analysis of Neoadjuvant ICI vs Cisplatin-Based Chemotherapy in Muscle-Invasive Bladder Cancer

Urologic Oncology: Seminars & Original Investigations


Additional Info

Urologic Oncology: Seminars & Original Investigations
Cost-Effectiveness Analysis of Neoadjuvant Immune Checkpoint Inhibition vs Cisplatin-Based Chemotherapy in Muscle Invasive Bladder Cancer
Urol. Oncol 2021 Mar 22;[EPub Ahead of Print], AR Khaki, Y Shan, RE Nelson, S Kaul, JL Gore, P Grivas, SB Williams

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading